Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors

NCT04282018 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04282018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
April 29, 2020
Completion date
August 28, 2024
Enrollment
97 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma